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Abstract Was the sharp upturn of life expectancy in the
Netherlands partly due to increased health care funding for
the elderly? I argue that there is nothing unusual to the
increasing life expectancy since the beginning of the
twenty-ﬁrst century, and that there is no observable rela-
tionship with changed health care funding whatsoever.
What was highly unusual was the rather dramatic lagging
of Dutch life expectancy between 1980 and 2000. The
reasons of this failure remain clouded in mystery.
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In this issue of EJE, Mackenbach et al. [1] argue that the
sharp upturn of life expectancy in the Netherlands has been
caused by effects of increased health care for the elderly,
an increase which is ‘‘facilitated’’ by a ‘‘relaxation’’ of
budgetary constraints. In clear words: the authors argue
that there was not enough money going around in Dutch
health care to deliver optimal care. The authors and I agree
about increased health care, but we disagree about the
impact of ‘‘budgetary constraints’’. I compared the evolu-
tion of life expectancy and of health care budgets of the
Netherlands with the rest of Europe (15 EU and EFTA
countries, without the smaller ones, the former socialist
nations and Greece, that has no data in the human mortality
database).
The evolution of life expectancy in the Netherlands is
unusual for a Western European country. Being the Euro-
pean champion in 1980 (see Table 1), female life expec-
tancy did not follow the rest of Europe countries for more
than 20 years. In 15 EU and EFTA countries, Dutch female
life expectancy at age 65 dropped in 20 years from the 1 to
the 11 position. The usual suspect, smoking, has been
blamed, and was partly responsible. But smoking could
never explain the lagging mortality decrease in women
aged 65 and older, as smoking was still poorly accepted in
these older birth cohorts born before the Second World
War [2].
The sharp upturn of life expectancy in the Netherlands,
starting around 2002, was remarkable. Mackenbach et al.
nicely demonstrate that these sharp changes were caused
by strong period effects, occurring in both genders and in
all age groups. But in the Table 1, one immediately notices
that the Netherlands merely held their position in the sec-
ond half of the peloton. In an European perspective, there
was nothing unusual about the increase of life expectancy
between 2000 and 2009. What was unusual was the relative
loss of life years in the Netherlands before, in the period
1980–2000: if the Netherlands had maintained its position
slightly before France, female life expectancy at age 65
was 2 years higher than it is in 2009.
The authors conclude that the upturn of life expectancy
was ‘‘facilitated’’ by increased health care spending. The
relation between health care funding and life expectancy
has always been tenuous: the US spends per capita twenty
times as much than Cuba for the same life expectancy.
Chile spends as much as South Africa, for a 27 year higher
life expectancy. If that can be blamed to AIDS: Chileans
live also 10 years longer than the Russians, who share the
life expectancy of … Bangladesh, a poor country that
spends 69 international dollar per head per year to health
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at the end of the ‘‘budgetary restrictive period’’, the Dutch
spent 2,340 USD per capita per year, and was remaining
stable in the 7th position. This changed after 2000, when
the Netherlands moved up to the third position, spending
close to 5,000 USD per capita.
The driver of increasing life expectancy in the European
(and many other) elderly is decreased cardiovascular
mortality, predominantly caused by health care technology
[3]. The authors argue that the period decreases in mor-
tality were seen in a wide variety of causes of death. I don’t
think so. The authors show (again beautifully), in webap-
pendix 2, that among women close to 90% of the life
expectancy gain (0.88 of 1.07 year) is caused by cardio-
vascular disease, ill deﬁned conditions and endocrine dis-
orders (webappendix 2). Death from ‘‘endocrine’’ disorders
is nearly identical to death from diabetes, often caused by
cardiovascular co-morbidity, death from ill deﬁned condi-
tions is often cardiovascular. Among men, the results are
similar, taking into account an extra 0.4 year added by
decreasing lung cancer and other smoking related mortal-
ity. Mortality decreased because of decreasing cardiovas-
cular mortality, as everywhere else. Strict rationing of the
highly effective statins before 2002 may have played a
role. But in the recent period with upturning life expec-
tancy, the older statins went off patent and became cheap:
they cannot explain any budgetary impact.
From an European perspective, trends in life expectancy
before 2000 and trends in health care budgets after 2000
show that the Dutch health care system is less efﬁcient than
the other European countries. It could not keep up with the
other EU countries in life expectancy before 2000. This
century, after the introduction of more competition in the
Dutch health care system, it did keep up again with
European life expectancy but, ironically, at the cost of
relatively increasing health care budgets. Success has many
fathers, defeat remains an orphan. While politicians and
public health scientists claim the success of increasing life
expectancy since 2002, the reasons of failure, why life
expectancy lagged so severely between 1980 and 2002, has
remained clouded in mystery.
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Table 1 Ranking of 15 EU and EFTA countries (excluding former
socialist economies) according to female life expectancy at age 65
and health care ﬁnancing ($ PPP per capita)
Life expectancy
at age 65 (women)
Health care ﬁnancing
1980 2000 2009 1990 2000 2008
Austria 14 9 9 5 3 4
Belgium 12 7 8 8 9 8
Denmark 7 14 15 4 6 5
Finland 10 10 6 9 11 12
France 2 1 1 2 5 7
Germany 11 8 12 4 5
Ireland 15 15 14 13 12 9
Italy 8 4 4 10 10 13
Netherlands 1 11 10 7 7 3
Norway 5 6 7 6 2 1
Portugal 13 12 13 14 15 15
Spain 6 3 2 12 14 14
Sweden 4 5 5 3 8 10
Switzerland 3 2 3 1 1 2
U K 91 31 11 1 1 3 1 1
Sources: Human mortality database and OECD
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